Adaptin Bio Company Description

Adaptin Bio, Inc., a biotechnology company, develops drug delivery technologies to deliver drugs and other compounds directly to target destinations within the body in the United States.

It provides Brain Bispecific T-cell Engager platform, a bispecific antibody technology to target and treat intracerebral malignancies, such as gliomas.

It develops APTN-101, a proprietary epidermal growth factor receptor variant III to eliminate malignant glioma tumors in a range of aggressive preclinical tumor models.

It caters to patients with oncology, CNS, autoimmune, and cardiovascular conditions, as well as healthcare professionals, researchers, and biopharma partners.

The company was founded in 2021 and is based in Charlotte, North Carolina.

Adaptin Bio, Inc.

Country	United States
Founded	2021
Industry	Biological Products, Except Diagnostic Substances
Employees	4
CEO	Michael Roberts

Contact Details

Address: 3540 Toringdon Way Charlotte, North Carolina 28277 United States
Phone	888 609 1498
Website	adaptinbio.com

Stock Details

Ticker Symbol	APTN
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Dr. Michael J. Roberts Ph.D.	Co-Founder, Chief Executive Officer, President and Director
Dr. Simon C. Pedder Ph.D.	Executive Chairman
Timothy L. Maness CPA	Chief Financial Officer
Dr. L. Arthur Hewitt Ph.D.	Chief Development Officer
Dr. Kirit Singh M.D., Ph.D.	Chief Scientific Consultant